Altered lipid metabolism in ADPKD patients treated with Tolvaptan

被引：0
|
作者：
Bargagli, Matteo [1 ]
Anderegg, Manuel [2 ]
Huynh-Do, Uyen [2 ]
Vogt, Bruno [2 ]
Ferraro, Pietro Manuel [3 ]
Fuster, Daniel [2 ]
机构：
[1] Univ Bern, Bern Univ Hosp, Dept Hypertens & Nephrol, Inselspital, Bern, Switzerland
[2] Univ Bern, Bern Univ Hosp, Dept Nephrol & Hypertens, Inselspital, Freiburgstr 75, CH-3070 Bern, Switzerland
[3] Fdn Policlin Univ A Gemelli IRCCS, UOS Terapia Conservat Malattia Renate Cronica, LA Gemelli 8, I-00768 Rome, Italy
来源：
SWISS MEDICAL WEEKLY | 2022年 / 152卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OC 32 / P
引用
收藏
页码：16S / 16S
页数：1
相关论文
共 50 条
  • [1] Plasma markers of mineral metabolism in ADPKD patients treated with tolvaptan
    Bargagli, Matteo
    Dhayat, Nasser A.
    Anderegg, Manuel
    Semmo, Mariam
    Uyen Huynh-Do
    Vogt, Bruno
    Ferraro, Pietro Manuel
    Fuster, Daniel G.
    SWISS MEDICAL WEEKLY, 2020, : 22S - 22S
  • [2] Altered Lipid Metabolism in Autosomal Dominant Polycystic Kidney Disease Patients Treated With Tolvaptan
    Bargagli, Matteo
    Anderegg, Manuel
    Ferraro, Pietro Manuel
    Fuster, Daniel G.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 160 - 161
  • [3] Tolvaptan treatment is associated with altered mineral metabolism parameters and increased bone mineral density in ADPKD patients
    Bargagli, Matteo
    Vetsch, Andri
    Anderegg, Manuel A.
    Dhayat, Nasser A.
    Huynh-Do, Uyen
    Faller, Nicolas
    Vogt, Bruno
    Ferraro, Pietro Manuel
    Fuster, Daniel G.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 (07) : 1645 - 1654
  • [4] URINARY LITHOGENIC RISK PROFILE IN ADPKD PATIENTS TREATED WITH TOLVAPTAN
    Bargagli, Matteo
    Dhayat, Nasser A.
    Anderegg, Manuel
    Semmo, Mariam
    Huynh-Do, Uyen
    Vogt, Bruno
    Ferraro, Pietro Manuel
    Fuster, Daniel Guido
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 12 - 12
  • [5] Urinary lithogenic risk profile in ADPKD patients treated with Tolvaptan
    Bargagli, Matteo
    Dhayat, Nasser
    Anderegg, Manuel
    Semmo, Mariam
    Huynh-Do, Uyen
    Vogt, Bruno
    Ferraro, Pietro Manuel
    Fuster, Daniel
    SWISS MEDICAL WEEKLY, 2019, : 26S - 26S
  • [6] Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan
    Bargagli, Matteo
    Dhayat, Nasser A.
    Anderegg, Manuel
    Semmo, Mariam
    Huynh-Do, Uyen
    Vogt, Bruno
    Ferraro, Pietro Manuel
    Fuster, Daniel G.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 15 (07): : 1007 - 1014
  • [7] Plasma Biomarkers of Mineral and Bone Disorder in ADPKD Patients Treated with Tolvaptan
    Bargagli, Matteo
    Dhayat, Nasser
    Anderegg, Manuel
    Huynh-do, Uyen
    Ferraro, Pietro Manuel
    Fuster, Daniel G.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 205 - 205
  • [8] Tolvaptan slows progression in ADPKD [Tolvaptan mindert die Progression bei ADPKD]
    Betzen C.
    Der Nephrologe, 2013, 8 (1): : 65 - 66
  • [9] BOTH HYDROCHLOROTHIAZIDE AND METFORMIN AMELIORATE AQUARETIC SIDE-EFFECTS IN ADPKD PATIENTS THAT ARE TREATED WITH TOLVAPTAN
    Kramers, Bart
    Koorevaar, Iris
    Aapkes, Sophie
    Dekkers, Claire
    Heerspink, Hiddo Lambers
    Gansevoort, Ronald
    Meijer, Esther
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 1 - 1
  • [10] DESCRIPTION OF GENETIC VARIANTS IN A COHORT OF TOLVAPTAN ADPKD PATIENTS
    Corradi, Valentina
    Caprara, Carlotta
    Pegoraro, Ofelia
    Mancini, Barbara
    Giuliani, Anna
    Gastaldon, Fiorella
    Giavarina, Davide
    Ronco, Claudio
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36
12345